Safety of Advanced Therapies in Clinical Trials vs Real World Experience
November 29th 2024Lisa J. Faia, MD asks the panel about their concerns regarding the safety of newer agents for the broad array of retinal vascular diseases, highlighting the similarities and differences between clinical trial outcomes and real-world results.
Read More
MOA and Improved Outcomes: Gaps in Measuring Real-World Results
November 22nd 2024Sumit Sharma, MD, FASRS ponders to the panel the root cause of improved outcomes with newer agents. The panel then highlights current gaps in measuring visual improvements beyond tools such as the OCT, emphasizing the need for patient-centered treatment plans.
Read More
Case 2: Diabetic Macular Edema With Severe Vision Loss
November 22nd 2024In the second case, Scott D. Walter, MD, MSc, FASRS presents a patient case of diabetic macular edema (DME) where each eye was treated with a different agent. Walter presents optical coherence tomograph (OTC) outcome similarities and differences in key criteria, such as neovascularization, micro aneurism leakage, and macular leakage.
Read More